260 related articles for article (PubMed ID: 18508484)
1. Her2 cross talk and therapeutic resistance in breast cancer.
Bender LM; Nahta R
Front Biosci; 2008 May; 13():3906-12. PubMed ID: 18508484
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.
Nahta R; Yu D; Hung MC; Hortobagyi GN; Esteva FJ
Nat Clin Pract Oncol; 2006 May; 3(5):269-80. PubMed ID: 16683005
[TBL] [Abstract][Full Text] [Related]
3. Growth factor receptor/steroid receptor cross talk in trastuzumab-treated breast cancer.
Collins DC; Cocchiglia S; Tibbitts P; Solon G; Bane FT; McBryan J; Treumann A; Eustace A; Hennessy B; Hill AD; Young LS
Oncogene; 2015 Jan; 34(4):525-30. PubMed ID: 24469058
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance.
Nahta R
Curr Med Chem; 2012; 19(7):1065-75. PubMed ID: 22229414
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer.
Mukohara T
Cancer Sci; 2011 Jan; 102(1):1-8. PubMed ID: 20825420
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
Kurokawa H; Arteaga CL
Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
[TBL] [Abstract][Full Text] [Related]
8. Trastuzumab resistance: role for Notch signaling.
Mehta K; Osipo C
ScientificWorldJournal; 2009 Dec; 9():1438-48. PubMed ID: 20024517
[TBL] [Abstract][Full Text] [Related]
9. HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.
Gajria D; Chandarlapaty S
Expert Rev Anticancer Ther; 2011 Feb; 11(2):263-75. PubMed ID: 21342044
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.
Gee JM; Robertson JF; Gutteridge E; Ellis IO; Pinder SE; Rubini M; Nicholson RI
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S99-S111. PubMed ID: 16113104
[TBL] [Abstract][Full Text] [Related]
11. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
12. [Her2 a paradigm for targeted therapy].
Marijon H; André F
Bull Cancer; 2011 Oct; 98(9):1011-7. PubMed ID: 21684838
[TBL] [Abstract][Full Text] [Related]
13. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor.
Chen C; Zhang Y; Zhang Y; Li J; Tsao SW; Zhang MY
Mol Cancer Ther; 2014 Jan; 13(1):90-100. PubMed ID: 24227890
[TBL] [Abstract][Full Text] [Related]
14. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.
Nahta R; Yuan LX; Zhang B; Kobayashi R; Esteva FJ
Cancer Res; 2005 Dec; 65(23):11118-28. PubMed ID: 16322262
[TBL] [Abstract][Full Text] [Related]
15. HER2 therapy: molecular mechanisms of trastuzumab resistance.
Nahta R; Esteva FJ
Breast Cancer Res; 2006; 8(6):215. PubMed ID: 17096862
[TBL] [Abstract][Full Text] [Related]
16. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.
Nahta R; Yuan LX; Du Y; Esteva FJ
Mol Cancer Ther; 2007 Feb; 6(2):667-74. PubMed ID: 17308062
[TBL] [Abstract][Full Text] [Related]
17. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
[TBL] [Abstract][Full Text] [Related]
18. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
Kataoka Y; Mukohara T; Shimada H; Saijo N; Hirai M; Minami H
Ann Oncol; 2010 Feb; 21(2):255-262. PubMed ID: 19633047
[TBL] [Abstract][Full Text] [Related]
19. Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.
Kalous O; Conklin D; Desai AJ; O'Brien NA; Ginther C; Anderson L; Cohen DJ; Britten CD; Taylor I; Christensen JG; Slamon DJ; Finn RS
Mol Cancer Ther; 2012 Sep; 11(9):1978-87. PubMed ID: 22761403
[TBL] [Abstract][Full Text] [Related]
20. A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.
Parra-Palau JL; Pedersen K; Peg V; Scaltriti M; Angelini PD; Escorihuela M; Mancilla S; Sánchez Pla A; Ramón Y Cajal S; Baselga J; Arribas J
Cancer Res; 2010 Nov; 70(21):8537-46. PubMed ID: 20978202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
